The Effects Of Nutraceutical, Turmeric And Its Active Ingredient Curcumin On Canine And Equine

945 Words4 Pages
In total, four experiments were conducted to determine the therapeutic and safety effects of the nutraceutical, turmeric and its active ingredient curcumin on canine and equine. Two studies were conducted on client-owned, moderately arthritic canines, studying the therapeutic and safety effect of curcumin’s anti-inflammatory properties. In Exp. 1, two different dosages, 500 mg, SID of 95% curcumin and 250 mg, BID of 95% liposomal-curcumin, were evaluated in ten moderately arthritic dogs over five months. The dogs in the 95% curcumin group had an overall greater significance in pain reduction by Day 60. Exp. 2, was a follow-up experiment to Exp. 1. In Exp. 2, two different dosages, 500 mg, SID or 100 mg, SID of 95% curcumin, were evaluated…show more content…
coli K-12 (P = 0.5114), E. coli general (P = 0.1083), C. difficile (P < 0.0001), and C. perfringens (P = 0.2439). The follow-up in vitro 24 h batch culture examined four different dosages (15 g, 20 g, 25 g, and 30 g) of 500 mg/g of LIPC, at reducing the concentration of opportunistic bacteria. These results were utilized to determine the dosing rate in vivo. Exp. 3, in vivo, evaluated the efficacy of antimicrobial and anti-inflammatory properties of LIPC dosed at 15, 25, and 35 g compared to a control. These results were utilized to determine the dosing rate in vivo. Exp. 4, in vivo, evaluated the efficacy of antimicrobial and anti-inflammatory properties of LIPC dosed at 15, 25, and 35 g compared to a control. In vivo, LIPC’s antimicrobial properties, at 15 g, significantly decreased (P = 0.02) SBEC compared to other treatments. In addition, C. perfringens tended (P = 0.12) to decrease as LIPC dose increased. Non-significant results in digestion, blood parameters, and range of motion suggest there were no adverse side effects from oral dosing increasing doses of curcumin. Valerate was significantly different among treatments (P = 0.02) with 0 having the greatest concentration compared to all other treatments. Moreover, valerate decreased linearly (P < 0.005) as LIPC dose increased. As LIPC dose
    Open Document